Stephen D. Hall - Concepedia

Author

Stephen D. Hall

Indiana University – Purdue University Indianapolis ORCID

Also Known As

DDRC Healthcare, Science Park, Plymouth, UK, Hall, S.D., Hall, Stephen D, Hall, Stephen D., M. E. Larkin, Robert A. Dean, S D Hall, S HALL, S Hall, S. D. HALL

280

Publications

18.3K

Citations

H-Index

209

Concepts

All Affiliations

Indiana University – Purdue University Indianapolis Indiana University School of Medicine Eli Lilly (United States)Sidney & Lois Eskenazi Hospital Aston University

About

Stephen D. Hall is an author at Indiana University – Purdue University Indianapolis specializing in medicine, pharmacology, and biochemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	41	56	7.6K
2	Health Sciences	14	14	1.3K
3	Natural Sciences	13	14	3.2K
4	Engineering	4	4	169
5	Public Health	2	2	632

Stephen D. Hall

163

Publications

17.5K

Citations

H-Index

Page 1

	Year	Citations
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression Peter Kuehl, Jiong Zhang, Yvonne Lin, Nature Genetics Cyp3a PromotersTranscriptional RegulationPlant Gene ExpressionNatural SciencesGenetics	2001	2.2K
The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity Bryan A. Ward, J. Christopher Gorski, David R. Jones, Journal of Pharmacology and Experimental Therapeutics	2003	591
Guidelines for the Management of Chronic Kidney Disease in HIV-Infected Patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America Samir K. Gupta, Joseph A. Eustace, Jonathan Winston, Clinical Infectious Diseases HypertensionImmunodeficienciesRenal PathologyImmunologyRenal Inflammation	2005	583
Comparative Metabolic Capabilities of CYP3A4, CYP3A5, and CYP3A7 J. Andrew Williams, Barbara J. Ring, Varon E. Cantrell, Drug Metabolism and Disposition	2002	463
Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity Naga Chalasani, Hisham Aljadhey, Joe Kesterson, Gastroenterology Higher RiskHepatologyLiver PhysiologyStatin HepatotoxicityElevated Liver Enzymes	2004	437
The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin* Jack Gorski, D. I. Jones, B HAEHNERDANIELS, Clinical Pharmacology & Therapeutics	1998	410
Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily Jack Gorski, Stephen D. Hall, D. I. Jones, Biochemical Pharmacology BiochemistryMedicineExperimental PharmacologyPharmacologyDrug Discovery	1994	396
Hepatic Cytochrome P450 2E1 Activity in Nondiabetic Patients With Nonalcoholic Steatohepatitis Naga Chalasani, Christopher J. Gorski, Ali Asghar, Hepatology	2003	339
An In Vitro Model for Predicting In Vivo Inhibition of Cytochrome P450 3A4 by Metabolic Intermediate Complex Formation David R. Jones, Stephen D. Hall Drug Metabolism and Disposition	2000	293
The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants Jiong Zhang, Peter Kuehl, E D Green, Pharmacogenetics	2001	290

Page 1